Factors influencing peripheral blood mononuclear cell-associated HIV-1 DNA level after long-term suppressive antiretroviral therapy in 236 patients

被引：32

作者：

Burgard, Marianne ^{[1
]}

Boufassa, Faroudy ^{[2
]}

Viard, Jean-Paul ^{[3
,4
]}

Garrigue, Isabelle ^{[5
]}

Ruffault, Annick ^{[6
]}

Izopet, Jacques ^{[7
]}

Vabret, Astrid ^{[8
]}

Descamps, Diane ^{[9
]}

Colson, Philippe ^{[10
]}

Seigneurin, Jean-Marie ^{[11
]}

Rouzioux, Christine ^{[1
,4
]}

机构：

[1] CHU Necker Enfants Malad, Virol Lab, AP HP, F-75015 Paris, France

[2] Univ Paris Sud, Hop Bicetre, INSERM, Dept Epidemiol,U822, F-94275 Le Kremlin Bicetre, France

[3] CHU Necker Enfants Malad, Serv Malad Infect, AP HP, F-75015 Paris, France

[4] Univ Paris 05, EA 3620, Paris, France

[5] CHU Bordeaux, Virol Lab, Bordeaux, France

[6] CHU Rennes, Virol Lab, Rennes, France

[7] CHU Toulouse, Virol Lab, Toulouse, France

[8] CHU Caen, Virol Lab, F-14000 Caen, France

[9] CHU Bichat, Virol Lab, AP HP, Paris, France

[10] CHU Marseille, Federat Microbiol Clin, Marseille, France

[11] CHU Grenoble, Virol Lab, F-38043 Grenoble, France

来源：

AIDS | 2009年 / 23卷 / 16期

关键词：

antiretroviral therapy; HIV-1; DNA; long-term therapy; suppressive therapy; viral load; CD4(+) T-CELLS; IMMUNODEFICIENCY-VIRUS TYPE-1; DISEASE PROGRESSION; LIFELONG PERSISTENCE; LATENT INFECTION; EXTENDED PERIODS; VIRAL LOAD; RESERVOIR; QUANTIFICATION; STABILITY;

D O I：

10.1097/QAD.0b013e32833032d4

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Objective: The objectives of this study were to determine whether peripheral blood mononuclear cell (PBMC)-associated HIV-1 DNA level in patients on long-term suppressive antiretroviral therapy (ART) was associated with plasma HIV-1 RNA level, CD4 cell count, and therapeutic factors throughout patient history. Design: Patients receiving triple or dual therapy with plasma HIV-1 RNA below detection limit for more than 3 years were recruited in a multicentric, cross-sectional study within the eight virology laboratories of the Agence Nationale de Recherche sur le SIDA et les Hepatites virales HIV quantification working group, each one in relation with a clinical center. Methods: PBMC-associated HIV-1 DNA was quantified using a standardized real-time PCR method in all laboratories. Results: A total of 236 patients was included. Median HIV-1 DNA was 2.8 log(10) copies/10(6) PBMCs (interquartile range 2.4-3.0). Univariate analysis showed PBMC HIV-1 DNA level to be related to pre-ART immuno-virologic status (plasma HIV-1 RNA zenith and CD4 cell count nadir) and to current CD4(+) T-cell count. HIV-1 DNA was lower in patients receiving ART with inferior virologic efficacy, as they also had a higher CD4 nadir and a lower HIV-1 RNA zenith than other patients. PBMC HIV-1 DNA level was not related to therapy duration, to time spent with undetectable HIV-1 RNA or to occurrence of a blip. Plasma HIV-1 RNA zenith and CD4 cell count nadir remained predictive of HIV-1 DNA level in the multivariate model which was associated with 22% of its variability. Conclusion: Whatever the duration of treatment, HIV-1 DNA level during ART gives a picture of the intensity of viral replication and immune deficiency reached before starting therapy. (C) 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins

引用

页码：2165 / 2171

页数：7